Litigation Details for Novo Nordisk Inc. v. Biocon Pharma Ltd. (D. Del. 2022)
✉ Email this page to a colleague
Novo Nordisk Inc. v. Biocon Pharma Ltd. (D. Del. 2022)
| Docket | 1:22-cv-00937 | Date Filed | 2022-07-14 |
| Court | District Court, D. Delaware | Date Terminated | 2024-03-21 |
| Cause | 35:271 Patent Infringement | Assigned To | Colm Felix Connolly |
| Jury Demand | None | Referred To | |
| Patents | 10,220,155; 10,357,616; 10,376,652; 11,097,063; 8,114,833; 8,684,969; 8,920,383; 9,132,239; 9,457,154; 9,616,180; 9,687,611; 9,775,953; 9,861,757; 9,968,659; RE46,363 | ||
| Link to Docket | External link to docket | ||
Small Molecule Drugs cited in Novo Nordisk Inc. v. Biocon Pharma Ltd.
Biologic Drugs cited in Novo Nordisk Inc. v. Biocon Pharma Ltd.
The biologic drugs covered by the patents cited in this case are ⤷ Start Trial , ⤷ Start Trial , ⤷ Start Trial , ⤷ Start Trial , ⤷ Start Trial , and ⤷ Start Trial .
Details for Novo Nordisk Inc. v. Biocon Pharma Ltd. (D. Del. 2022)
| Date Filed | Document No. | Description | Snippet | Link To Document |
|---|---|---|---|---|
| 2022-07-14 | External link to document | |||
| >Date Filed | >Document No. | >Description | >Snippet | >Link To Document |
